News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Canterbury Health Laboratories (NZ) Adopts Roche NimbleGen, Inc Microarray Cytogenetics Solution for Mental Retardation Research


11/16/2010 11:50:13 AM

MADISON, Wis.--(BUSINESS WIRE)--Roche NimbleGen (SWX:RO) (SWX:ROG) (Pink Sheets: RHHBY) today announced that one of New Zealand’s largest medical laboratories has adopted the NimbleGen CGX Cytogenetics Microarray Solution. Canterbury Health Laboratories has implemented the NimbleGen workflow solution for Cytogenetics including arrays, reagents, instruments, and software at their core facility in Christchurch, New Zealand. The laboratory will be initially implementing the NimbleGen CGX-12 arrays for their research on developmental delay and mental retardation. These arrays provide targeted cytogenetic content based on the analysis of over 40,000 research samples and include several multiplex formats that enable accurate, high-resolution analysis of up to 12 samples in parallel.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES